Federal health officials have declined to approve the psychedelic drug MDMA as a therapy for PTSD. Drugmaker Lykos ...

The US Food and Drug Administration's (FDA) decision not to approve midomafetamine-assisted therapy (MDMA-AT) for ...

Lykos Therapeutics filed an application for FDA approval of its version of MDMA-assisted therapy for PTSD in February 2024.

In a previous blog on the use of psychedelics to treat mental health disorders, we reported that the US Food and Drug Administration (FDA) ...

Critics addressed the elephant in the room during the FDA’s first public meeting on trauma since its decision to delay ...

The FDA rejected MDMA therapy as a treatment for PTSD, with the advisory committee saying there is not enough evidence it was safe or effective. A setback to the use of psychedelics for the treatment ...

A Food and Drug Administration (FDA) advisory panel overwhelmingly rejected MDMA-assisted therapy for treating post-traumatic ...

Advocates are pushing for approval of psychedelic-assisted therapy from the FDA, seeking a means of therapy without fear of ...

As Psychiatric Times reported, this decision puts on hold what could have been a landmark approval for the treatment of PTSD with MDMA, also known as midomafetamine. Despite the setback, Lykos ...

Delve into the psychedelic-assisted therapy market and investors' sentiment after the FDA's decision about Lykos' MDMA ...

The FDA was following the recommendation of an advisory panel that had expressed several concerns about two Phase 3 studies ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...